Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$734M |
| 2 |
Adobe
ADBE
|
+$488M |
| 3 |
Merck
MRK
|
+$443M |
| 4 |
Tesla
TSLA
|
+$366M |
| 5 |
AGN
Allergan plc
AGN
|
+$315M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$682M |
| 2 |
Perrigo
PRGO
|
+$585M |
| 3 |
Gilead Sciences
GILD
|
+$556M |
| 4 |
EMC
EMC CORPORATION
EMC
|
+$432M |
| 5 |
Morgan Stanley
MS
|
+$401M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.29% |
| 2 | Consumer Discretionary | 15.4% |
| 3 | Communication Services | 11.3% |
| 4 | Technology | 10.76% |
| 5 | Energy | 10.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alphabet (Google) Class C
GOOG
$4.19T
| $3.03B | 2.97% |
108,523,935
-1,664,737
| -2% | -$42.1M |
|
2
Mastercard
MA
$521B
| $2.84B | 2.78% |
33,964,710
-1,422,910
| -4% | -$106M |
|
3
Apple
AAPL
$4.67T
| $2.7B | 2.65% |
134,869,308
-18,608,772
| -12% | -$352M |
|
4
Amazon
AMZN
$2.87T
| $2.44B | 2.39% |
122,384,300
-14,639,040
| -11% | -$263M |
|
5
Biogen
BIIB
$32.3B
| $1.82B | 1.79% |
6,505,831
+117,882
| +2% | +$30.5M |
|
6
Booking.com
BKNG
$155B
| $1.8B | 1.77% |
38,734,825
-3,017,500
| -7% | -$134M |
|
|
MON
7
DELISTED
Monsanto Co
MON
| $1.65B | 1.62% |
14,136,589
-437,785
| -3% | -$47.8M |
|
|
8
Bristol-Myers Squibb
BMY
$136B
| $1.59B | 1.56% |
29,839,467
+14,403,585
| +93% | +$734M |
|
9
TJX Companies
TJX
$149B
| $1.41B | 1.38% |
44,273,168
-3,097,850
| -7% | -$93.9M |
|
10
Boeing
BA
$166B
| $1.37B | 1.34% |
10,018,379
-1,118,541
| -10% | -$145M |
|
11
Meta Platforms (Facebook)
META
$1.47T
| $1.33B | 1.3% |
24,298,965
-1,442,348
| -6% | -$72.4M |
|
12
Visa
V
$712B
| $1.3B | 1.27% |
23,291,408
+2,234,072
| +11% | +$113M |
|
13
Nike
NKE
$58.7B
| $1.28B | 1.25% |
32,515,348
-2,229,452
| -6% | -$85.3M |
|
14
Goldman Sachs
GS
$301B
| $1.26B | 1.24% |
7,114,238
+957,249
| +16% | +$158M |
|
|
15
Gilead Sciences
GILD
$181B
| $1.22B | 1.2% |
16,228,862
-7,985,052
| -33% | -$556M |
|
|
AGN
16
DELISTED
Allergan Inc
AGN
| $1.19B | 1.17% |
10,727,036
+1,299,673
| +14% | +$124M |
|
|
LNKD
17
DELISTED
LinkedIn Corporation
LNKD
| $1.18B | 1.16% |
5,455,470
-245,878
| -4% | -$56M |
|
|
PCP
18
DELISTED
PRECISION CASTPARTS CORP
PCP
| $1.17B | 1.15% |
4,350,713
+206,315
| +5% | +$51.9M |
|
19
Salesforce
CRM
$211B
| $1.15B | 1.13% |
20,808,793
-2,185,260
| -10% | -$117M |
|
|
ALXN
20
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.12B | 1.1% |
8,397,889
-237,117
| -3% | -$28.5M |
|
21
Walt Disney
DIS
$187B
| $1.11B | 1.09% |
14,523,846
-520,369
| -3% | -$36M |
|
22
Mondelez International
MDLZ
$79.6B
| $1.11B | 1.09% |
31,422,241
-728,667
| -2% | -$24.2M |
|
23
Costco
COST
$419B
| $1.08B | 1.06% |
9,086,063
-339,462
| -4% | -$40.6M |
|
|
CXO
24
DELISTED
CONCHO RESOURCES INC.
CXO
| $1.01B | 0.99% |
9,387,248
+242,549
| +3% | +$26.2M |
|
25
Vertex Pharmaceuticals
VRTX
$137B
| $1B | 0.98% |
13,474,878
-469,415
| -3% | -$32.7M |
|
Similar funds
Jennison Associates's Q4 2013 Portfolio in Review
As of Q4 2013, Jennison Associates held 759 positions worth $102B, up 6.9% from $95.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q4 2013 filing shows 79 new, 184 increased, 411 reduced and 54 closed positions. Its largest new stake was Allergan plc: 2,016,619 shares worth $339M. The largest sale was UnitedHealth, an estimated $682M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q4 2013 buy was Allergan plc: 2,016,619 shares worth $339M.
- Jennison Associates added most to Bristol-Myers Squibb in Q4 2013, an estimated $734M increase.
- Jennison Associates's biggest Q4 2013 reduction was UnitedHealth, cutting an estimated $682M.
- Jennison Associates fully exited Perrigo in Q4 2013, selling an estimated $585M.
- Jennison Associates's ten largest holdings make up 20% of its $102B portfolio in Q4 2013.
- Jennison Associates opened 79 new positions and closed 54 in Q4 2013.
- Jennison Associates's portfolio value rose 6.9% quarter-over-quarter to $102B.
Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.